Sinopharm Group CoSHTDF -2.67%78 ROE % is 9.07% as of Dec. 2025, which is 33% below its 10-year median of 13.53. GuruFocus rates SHTDF with a GF Score™ of 78/100 and a GF Value™ of $3.03 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 115 Medical Distribution companies, Sinopharm Group Co ranks better than 60.87% on this metric.
The historical rank and industry rank for Sinopharm Group Co's ROE % or its related term are showing as below:
SHTDF'
s ROE % Range Over the Past 10 Years
Min: 8.91 Med: 13.53 Max: 16.3
Current: 8.91
During the past 13 years, Sinopharm Group Co's highest ROE % was 16.30%. The lowest was 8.91%. And the median was 13.53%.
SHTDF's ROE % is ranked better than 60.87% of 115
companies
in the Medical Distribution industry
Industry Median: 7.1
vs SHTDF: 8.91
Sinopharm Group Co (OTCPK:SHTDF) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Sinopharm Group Co ROE % Related Terms
Sinopharm Group Co ROE % Historical Data
* Premium members only.
The historical data trend for Sinopharm Group Co's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sinopharm Group Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co ROE % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's ROE % distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Sinopharm Group Co (SHTDF) has a ROE % of 9.07% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sinopharm Group Co and its competitors. This is 33% below median its historical median of 13.53. Over the past decade, Sinopharm Group Co's ROE % has ranged from 8.91 to 16.30. According to the industry distribution chart, Sinopharm Group Co ranks #45 out of 115 companies in the Medical Distribution industry, placing it in the top 39.1%.
Is Sinopharm Group Co's ROE % too high?
Sinopharm Group Co's current ROE % of 9.07% is 33% below median its 10-year median of 13.53. Over the past 10 years, this metric has ranged from a low of 8.91 to a high of 16.30. The Medical Distribution industry median ROE % is 7.10. Sinopharm Group Co's value of 9.07% is 27.7% above this industry median. Based on the distribution chart, Sinopharm Group Co ranks #45 out of 115 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Sinopharm Group Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sinopharm Group Co's ROE % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sinopharm Group Co ranks #45 out of 115 companies for ROE %. This puts Sinopharm Group Co in the upper half of its industry. The industry median ROE % is 7.10. Sinopharm Group Co's value of 9.07% is 27.7% above this benchmark. Historically, Sinopharm Group Co's own ROE % has ranged from 8.91 to 16.30 over the past decade. While the company's 10-year median is 13.53 vs. the industry median of 7.10, Sinopharm Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Medical Distribution company?
The median ROE % among Medical Distribution companies is 7.10, based on 115 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sinopharm Group Co's current ROE % of 9.07% is 27.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Sinopharm Group Co and its competitors. For the Medical Distribution industry, the median ROE % is 7.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sinopharm Group Co's current ROE % is 9.07%, which is 33% below median its own 10-year median of 13.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sinopharm Group Co stock overvalued right now?
Based on GuruFocus' analysis, Sinopharm Group Co (SHTDF) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.03, compared to a current price of $2.29 — trading 24.5% below its estimated fair value. The current ROE % is 9.07%, which is 33% below median its 10-year median of 13.53 and 27.7% above the Medical Distribution industry median of 7.10. Sinopharm Group Co's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Sinopharm Group Co (SHTDF), the current ROE % is 9.07% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sinopharm Group Co (SHTDF) Overvalued in 2026?
Based on GuruFocus' analysis, Sinopharm Group Co stock appears to be undervalued.
The current stock price of $2.29 is trading 24.5% below its estimated GF Value™ of $3.03.
GuruFocus considers Sinopharm Group Co to be Modestly Undervalued.
Key valuation signals for SHTDF:
ROE %: 9.07% (33% below median its 10-year median of 13.53)
GF Value™: $3.03 vs. price of $2.29 (24.5% below fair value)
Industry Position: 27.7% above the Medical Distribution median (#45 of 115)
No single metric tells the full story. See the SHTDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
78GF Score
Get the complete analysis for SHTDF
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHTDF has been successfully added to your 
